Please login to the form below

Not currently logged in
Email:
Password:

EMA reviews Multaq's CVD risk

The European Medicines Agency is to review the cardiovascular risk of Sanofi's anti-arrhythmic medicine Multaq following serious adverse events in the company's discontinued PALLAS study

The European Medicines Agency (EMA) is to review the cardiovascular risk of Sanofi's anti-arrhythmic medicine Multaq (dronedarone) following serious adverse events in the company's discontinued PALLAS study.

Results from the study, which investigated the effects of Multaq in more than 3,149 patients over 65 years of age with permanent atrial fibrillation, found a higher rate of events and hospitalisations with Multaq when compared with placebo.

The EMA pointed out that the patient population involved in the PALLAS study is different from the population for which Multaq is currently approved.

A review by the Agency's Committee for Medicinal Products for Human Use (CHMP) concerning the benefit-risk balance of Multaq following reports of severe liver injury commenced in January, with the scope of this review now extended to also assess new information from the PALLAS study.

The CHMP will determine the need for any further action at its next meeting on July 18-21, 2011.

12th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics